Business
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p<0.0001) - Change from baseline in AHV was superior to placebo at Week 52 with a mean treatment difference against placebo of +2.10 cm/year; the LS mean was +1.74 cm/year - In a pre-specified exploratory analysis of the key secondary endpoint, oral infigratinib achieved the first statistically significant improvement in body proportionality against placebo in achondroplasia, demonstrating an LS mean trea
About this update from Bridgebio Pharma, Inc.
[{"type":"image","alt":"BridgeBio Pharma, Inc.","displaySize":"","headline":null,"caption":"BridgeBio Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":47,"url":"https://media.zenfs.com/en/globenewswire.com/67d229c5dfa70aa930ee69ce2872e9be"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Z3roQwquAczfyVwH352A4g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/67d229c5dfa70aa930ee69ce2872e9be","width":300,"height":47}},"lazy":false},{"type":"text","content":"- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p<0.0001)","length":104,"tagName":"p"},{"type":"text","content":"- Change from baseline in AHV was superior to placebo at Week 52 with a mean treatment difference against placebo of +2.10 cm/year; the LS mean was +1.74 cm/year","length":161,"tagName":"p"},{"type":"text","content":"- In a pre-specified exploratory analysis of the key secondary endpoint, oral infigratinib achieved the first statistically significant improvement in body proportionality against placebo in achondroplasia, demonstrating an LS mean treatment difference of -0.05 (p<0.05) against placebo in children younger than 8 years old (>50% of the participants)","length":356,"tagName":"p"},{"type":"text","content":"- PROPEL 3 successfully met the key secondary endpoint of change from baseline in height Z-score (achondroplasia reference population) at Week 52 (p<0.0001), with an LS mean increase on the treatment arm of +0.41 SD","length":218,"tagName":"p"},{"type":"text","content":"- Oral infigratinib was well tolerated, with no discontinuations or serious adverse events related to study drug, 3 cases (4%) of hyperphosphatemia considered mild and transient with not a single case requiring either dose reduction or discontinuation, and no adverse events associated with inhibition of FGFR1 or 2 (e.g., retinal or corneal)","length":342,"tagName":"p"},{"type":"text","content":"- NDA and MAA submissions planned in second half of 2026 for achondroplasia; oral infigratinib is the only therapeutic option in development for achondroplasia to have Breakthrough Therapy Designation from the FDA","length":213,"tagName":"p"},{"type":"text","content":"- Given the strength of these data, BridgeBio plans to accelerate the development of oral infigratinib in ...